Type of Cancer
Breast Oncology
Phase
Division (Location)
Study ID
NCT#
Brief Description
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.